UniProtKB/Swiss-Prot Q9NRR2: Variant p.Val60Met

Tryptase gamma
Gene: TPSG1
Feedback?

Variant information Variant position:

60 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Valine (V) to Methionine (M) at position 60 (V60M, p.Val60Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Polymorphism:

There are two alleles; gamma-I and gamma-II which differ by 5 residues. Additional information on the polymorphism described.
Variant description:

In allele gamma-II. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs760357 [ dbSNP | Ensembl ]

Sequence information Variant position:

60 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

321 The length of the canonical sequence.
Location on the sequence:

GGHAAPAGAWPWQASLRLRR V HVCGGSLLSPQWVLTAAHCF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         GGHAAPAGAWPWQASLRLRRVHVCGGSLLSPQWVLTAAHCF

Mouse                         GGHAAPAGTWPWQASLRLHKVHVCGGSLLSPEWVLTAAHCF

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	20 – 321	Tryptase gamma
Chain	38 – 321	Tryptase gamma heavy chain
Domain	38 – 270	Peptidase S1
Active site	78 – 78	Charge relay system
Disulfide bond	26 – 145	Interchain (between light and heavy chains)

Literature citations
Identification of a new member of the tryptase family of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension.
Wong G.W.; Tang Y.; Feyfant E.; Sali A.; Li L.; Li Y.; Huang C.; Friend D.S.; Krilis S.A.; Stevens R.L.;
J. Biol. Chem. 274:30784-30793(1999)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA]; VARIANTS MET-60; ILE-239 AND LEU-288; Characterization of human gamma-tryptases, novel members of the chromosome 16p mast cell tryptase and prostasin gene families.
Caughey G.H.; Raymond W.W.; Blount J.L.; Hau L.W.; Pallaoro M.; Wolters P.J.; Verghese G.M.;
J. Immunol. 164:6566-6575(2000)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS MET-60; MET-126; THR-132; SER-160; ILE-204; ILE-239 AND LEU-288;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.